PF 4531083

Drug Profile

PF 4531083

Alternative Names: PF-04531083

Latest Information Update: 14 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Analgesics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain; Postoperative pain

Most Recent Events

  • 10 Jul 2012 Pfizer terminates phase II trial in Postoperative pain in USA (NCT01512160)
  • 22 May 2012 Pfizer completes enrolment in its phase II trial for Postoperative pain in USA (NCT01512160)
  • 10 May 2012 Discontinued - Phase-I for Pain in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top